Table 1 Basic characteristics of included guidelines
CPG code | Year | Country | Developing Organization | Title |
|---|---|---|---|---|
Global cardiovascular disease | ||||
 CVD 1 [15] | 2012 | Australia | National Vascular Disease Prevention Alliance | Guidelines for the management of absolute cardiovascular disease risk |
 CVD 2 [16] | 2014 | UK | National Institute for Health and Care Excellence | Prevention of cardiovascular disease (PH25) |
 CVD 3 [17] | 2016 | EU | European Society of Cardiology | European Guidelines on cardiovascular disease prevention in clinical practice |
 CVD 4 [18] | 2017 | UK | Scottish Intercollegiate Guidelines Network | Risk estimation and the prevention of cardiovascular disease |
 CVD 5 [19] | 2019 | Netherlands | Dutch College of General Practitioners | Cardiovascular risk management (M84) |
 CVD 6 [20] | 2018 | Australia | National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand | Guidelines for the prevention, detection, and management of heart failure in Australia |
 CVD 7 [21] | 2019 | U.S | American College of Cardiology & American Heart Association Task Force on Clinical Practice Guidelines | Guideline on the primary prevention of cardiovascular disease |
Lifestyle behavior | ||||
 LSt 1 [22] | 2012 | U.S | U.S. Preventive Services Task Force | Behavioral counseling interventions to promote a healthful diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors |
 LSt 2 [23] | 2014 | U.S | American College of Cardiology Foundation & American Heart Association | Guideline on lifestyle management to reduce cardiovascular risk |
 LSt 3 [24] | 2014 | UK | National Institute for Health and Care Excellence | Behavior change: individual approaches (PH49) |
Overweight & obesity | ||||
 OW 1 [25] | 2012 | U.S | U.S. Preventive Services Task Force | Screening for and management of obesity in adults |
 OW 2 [26] | 2013 | Australia | National Health and Medical Research Council | Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia |
 OW 3 [27] | 2014 | U.S | American College of Cardiology Foundation & American Heart Association & The Obesity Society | Guideline for the management of overweight and obesity in adults |
 OW 4 [28] | 2014 | U.S | Department of Defense & Department of Veterans Affairs& Veterans Health Administration | Clinical practice guideline for screening and management of overweight and obesity |
 OW 5 [29] | 2014 | UK | National Institute for Health and Care Excellence | Obesity prevention (CG43) |
 OW 6 [30] | 2015 | Canada | Canadian Task Force on Preventive Health Care | Recommendations for prevention of weight gain and use of behavioral and pharmacological interventions to manage overweight and obesity in adults in primary care |
 OW 7 [31] | 2015 | UK | National Institute for Health and Care Excellence | Maintaining a healthy weight and preventing excess weight gain among adults and children |
Blood lipids & cholesterol | ||||
 LCh 1 [32] | 2014 | UK | National Institute for Health and Care Excellence | Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (cg181) |
 LCh 2 [33] | 2014 | U.S | Department of Defense & Department of Veterans Affairs & Veterans Health Administration | Clinical practice guideline for the management of dyslipidemia for cardiovascular risk reduction |
 LCh 3 [34] | 2018 | U.S | American College of Cardiology & American Heart Association Task Force on Clinical Practice Guidelines | Guideline on the management of blood cholesterol |
 LCh 4 [35] | 2019 | EU | The Task Force for the management of dyslipidemias of the European Society of Cardiology and European Atherosclerosis Society | Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk |
Hypertension | ||||
 BP 1 [36] | 2014 | U.S | Department of Defense & Department of Veterans Affairs & Veterans Health Administration | Clinical practice guideline for the diagnosis and management of hypertension in the primary care setting |
 BP 2 [37] | 2014 | U.S | Community Preventive Services Task Force | Team-based care to improve blood pressure control |
 BP 3 [38] | 2020 | Canada | Hypertension Canada | Comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children |
Blood glucose & type 2 diabetes mellitus | ||||
 DM 1 [39] | 2013 | Canada | Canadian Diabetes Association | Clinical practice guidelines for the prevention and management of diabetes in Canada: Introduction |
 DM 2 [40] | 2014 | UK | National Institute for Health and Care Excellence | Type 2 diabetes prevention: population and community-level interventions (PH35) |
 DM 3 [41] | 2019 | EU | European Society of Cardiology & European Association for the Study of Diabetes | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases |